Sarah Eshelman
Family · Bucyrus, OHNPI 1710415591
Payments from drug & device makers
Across 239 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$521
- AbbVie$426
- Novartis$380
- Lilly USA, LLC$326
- GSK$323
- Novo Nordisk$266
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,011100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $521 |
| AbbVie | 25 | $426 |
| Novartis | 21 | $380 |
| Lilly USA, LLC | 21 | $326 |
| GSK | 23 | $323 |
| Novo Nordisk | 17 | $266 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $206 |
| Bayer | 12 | $173 |
| Boehringer Ingelheim | 9 | $159 |
| Johnson & Johnson | 7 | $132 |
| Amgen | 7 | $130 |
| Phathom Pharmaceuticals, Inc. | 5 | $107 |
| Pfizer | 5 | $88 |
| Exact Sciences | 4 | $83 |
| Astellas Pharma US Inc | 4 | $78 |
| Shield Therapeutics Inc | 4 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $62 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| Cipher Pharmaceuticals US LLC | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 2 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Medtronic | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Abbott | 1 | $14 |
How this compares
$4,011 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 138 | $102,490 |
| OzempicSemaglutide | 77 | $91,253 |
| EliquisApixaban | 70 | $53,218 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $41,060 |
| XareltoRivaroxaban | 30 | $28,987 |
| KerendiaFinerenone | 37 | $24,459 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $19,533 |
| FarxigaDapagliflozin Propanediol | 20 | $16,848 |
| TrulicityDulaglutide | 15 | $14,423 |
| JanuviaSitagliptin Phosphate | 13 | $11,890 |
| MyrbetriqMirabegron | 11 | $10,947 |
| Repatha SyringeEvolocumab | 12 | $6,616 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $6,603 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $4,770 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 157 | $4,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Pradaxa | $159 | $104,731150 claims |
| Novo NordiskOzempic | $266 | $91,25377 claims |
| PfizerEliquis | $88 | $53,21870 claims |
| GSKTrelegy Ellipta | $323 | $41,06064 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $521 | $36,38251 claims |
| Johnson & JohnsonXarelto | $132 | $28,98730 claims |
| BayerKerendia | $173 | $24,45937 claims |
| Lilly USA, LLCTrulicity | $326 | $14,42315 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $10,94711 claims |
| Esperion Therapeutics, Inc.Nexlizet | $50 | $4,77012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Bucyrus
- Jessica HannanBucyrus$18K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.